Latest news

• Sandoz finally wins FDA approval for Neulasta biosimilar

  Global sales of biopharmaceuticals grew 27%, according to the third quarter report, which was driven by strong double-digit growth in Europe from Rixathon (rituximab), Hyrimoz (adalimumab) and Erelzi (etanercept).

• Novartis expands its generics franchise with natalizumab biosimilar

  Sandoz’s sales in the  second quarter of 2019 climbed 3% to $2.4bn, with double-digit gains in Europe for its trio of biosimilars rixathon (rituximab), hyrimoz (adalimumab) and erelzi ... competition. Despite Sandoz gaining approval in 2016for erelzi,

• Amgen wins Enbrel patent case, knocking back Sandoz's biosimilar plan

  The Novartis subsidiary was looking to the case in the District Court of New Jersey to clear some of the barriers to the commercial launch of the biosimilar, called Erelzi ... We will appeal this decision, and look forward to presenting our case to the

• Novartis raises 2019 guidance as new products gather speed

  Vas Narasimhan. In the second quarter Sandoz sales were up 3% to $2.4bn, with double-digit gains in Europe for its trio of biosimilars - Rixathon (rituximab), Hyrimoz (adalimumab) and Erelzi

• Alcon spun off, leaner Novartis raises profit forecast

  Despite discussions of a possible sell-off, Sandoz’s biosimilars division is performing well, with double digit growth in Europe thanks to products such as Rixathon (rituximab), Hyrimoz (adalimumab) and Erelzi